Heart failure & cardiomyopathiesCohort study
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis
- Cohort study
Authors' conclusion
Frailty is common in ATTR-CA and is independently linked to increased mortality risk.
Study context
- Population
- Patients with transthyretin cardiac amyloidosis (ATTR-CA)
- Participants
- 880 patients
- Exposure
- Frailty categories by Clinical Frailty Scale
- Clinical Frailty Scale (CFS) 4 or 5n = 364
- CFS 6 or 7n = 129
- CFS 8 or 9n = 9
- Outcome
- Prevalence of frailty (CFS), its determinants and association with mortality
Main finding
As reported in the abstract
Frailty prevalence
- Frailty (any)
- 502 (57.1%)
Observational data: associations, not effects.
Further findings
Mortality by frailty severity
- Mortality rates increased incrementally with frailty severity (deaths per 100 person-years)
- 2.9 vs 11.0 vs 21.1 vs 40.9; log-rank P < 0.001
- Frailty independently associated with higher mortality risk across all age groups, genotypes and disease stages
Independent predictors of worsening frailty
- Older age, female sex, non-p.(V142I) hereditary ATTR-CA variants and National Amyloidosis Centre stage 3 disease
Original publication
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis. JACC CardioOncol. Published 12 March 2025. doi:10.1016/j.jaccao.2025.01.018
Summarised from the published abstract; every number is checked against it